{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:25:42Z","timestamp":1790738742583,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,3,11]],"date-time":"2017-03-11T00:00:00Z","timestamp":1489190400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012781","name":"MSD K.K.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00280-016-3237-x","type":"journal-article","created":{"date-parts":[[2017,3,10]],"date-time":"2017-03-10T20:09:41Z","timestamp":1489176581000},"page":"651-660","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)"],"prefix":"10.1007","volume":"79","author":[{"given":"Naoya","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Takenouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Ihn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Uchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Inozume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Kiyohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Uhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidefumi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shimamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,11]]},"reference":[{"key":"3237_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-3-319-22539-5_4","volume":"167","author":"N Kibbi","year":"2016","unstructured":"Kibbi N, Kluger H, Choi JN (2016) Melanoma: Clinical Presentations. Cancer Treat Res 167:107\u2013129. doi: 10.1007\/978-3-319-22539-5_4","journal-title":"Cancer Treat Res"},{"key":"3237_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/978-3-319-22539-5_13","volume":"167","author":"HL Spencer","year":"2016","unstructured":"Spencer HL, Mehnert JM (2016) Mucosal Melanoma: Epidemiology, Biology and Treatment. Cancer Treat Res 167:295\u2013320. doi: 10.1007\/978-3-319-22539-5_13","journal-title":"Cancer Treat Res"},{"key":"3237_CR3","unstructured":"Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11"},{"key":"3237_CR4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69\u201390","journal-title":"CA Cancer J Clin"},{"key":"3237_CR5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10147-007-0751-1","volume":"13","author":"K Ishihara","year":"2008","unstructured":"Ishihara K, Saida T, Otsuka F, Yamazaki N et al (2008) Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol 13:33\u201341","journal-title":"Int J Clin Oncol"},{"key":"3237_CR6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00008390-200412000-00016","volume":"14","author":"JW Chang","year":"2004","unstructured":"Chang JW, Yeh KY, Wang CH, Yang TS, Chiang HF, Wei FC et al (2004) Malignant melanoma in Taiwan: a prognostic study of 181 cases. Melanoma Res 14:537\u2013541","journal-title":"Melanoma Res"},{"key":"3237_CR7","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1023\/A:1018432632528","volume":"8","author":"RD Cress","year":"1997","unstructured":"Cress RD, Holly EA (1997) Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of California cancer registry data, 1988\u201393. Cancer Causes Control 8:246\u2013252","journal-title":"Cancer Causes Control"},{"issue":"8","key":"3237_CR8","doi-asserted-by":"publisher","first-page":"10339","DOI":"10.1007\/s13277-016-4914-4","volume":"37","author":"M Hao","year":"2016","unstructured":"Hao M, Zhao G, Du X, Yang Y, Yang J (2016) Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China. Tumour Biol 37(8):10339\u201310348. doi: 10.1007\/s13277-016-4914-4 (Epub ahead of print)","journal-title":"Tumour Biol"},{"key":"3237_CR9","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1634\/theoncologist.2015-0522","volume":"21","author":"D Kuk","year":"2016","unstructured":"Kuk D, Shoushtari AN, Barker CA, Panageas KS, Munhoz RR, Momtaz P et al (2016) Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis. Oncologist 21:848\u2013854. doi: 10.1634\/theoncologist.2015-0522","journal-title":"Oncologist"},{"issue":"26","key":"3237_CR10","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","volume":"24","author":"JA Curtin","year":"2006","unstructured":"Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24(26):4340\u20134346","journal-title":"J Clin Oncol"},{"key":"3237_CR11","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135\u20132147","journal-title":"N Engl J Med"},{"issue":"2","key":"3237_CR12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1755-148X.2010.00671.x","volume":"23","author":"D Handolias","year":"2010","unstructured":"Handolias D, Salemi R, Murray W, Tan A, Liu W, Viros A et al (2010) Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigm Cell. Melanoma Res 23(2):210\u2013215","journal-title":"Melanoma Res"},{"issue":"7","key":"3237_CR13","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/1078-0432.CCR-10-2346","volume":"17","author":"Y Kong","year":"2011","unstructured":"Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT et al (2011) Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 17(7):1684\u20131691","journal-title":"Clin Cancer Res"},{"key":"3237_CR14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/pcmr.12279","volume":"27","author":"SJ Furney","year":"2014","unstructured":"Furney SJ, Turajlic S, Stamp G, Thomas JM, Hayes A, Strauss D et al (2014) The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. Pigment Cell. Melanoma Res 27:835\u2013838","journal-title":"Melanoma Res"},{"issue":"2","key":"3237_CR15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 11:369(2):134\u2013144","journal-title":"N Engl J Med"},{"key":"3237_CR16","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","volume":"21","author":"A Patnaik","year":"2105","unstructured":"Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M et al (2105) Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 21:4286\u20134293","journal-title":"Clin Cancer Res"},{"key":"3237_CR17","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908\u2013918","journal-title":"Lancet Oncol"},{"key":"3237_CR18","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521\u20132532","journal-title":"N Engl J Med"},{"key":"3237_CR19","doi-asserted-by":"publisher","unstructured":"Robert C, Joshua AM, Weber JS, Ribas A, Hodi FS, Kefford RF et al (2014) Pembrolizumab (Pembro; MK-3475) for advanced melanoma (MEL): randomized comparison of two dosing schedules. Ann Oncol 25 (suppl 4). doi: 10.1093\/annonc\/mdu438.42","DOI":"10.1093\/annonc\/mdu438.42"},{"key":"3237_CR20","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R et al (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. The Lancet 384:1109\u20131117","journal-title":"The Lancet"},{"issue":"3","key":"3237_CR21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10637-016-0347-6","volume":"34","author":"T Shimizu","year":"2016","unstructured":"Shimizu T, Seto T, Hirai F, Takenoyama M, Nosaki K, Tsurutani J et al (2016) Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Invest New Drugs 34(3):347\u2013354","journal-title":"Invest New Drugs"},{"key":"3237_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1051","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. doi: 10.1001\/jamaoncol.2016.1051 (Epub ahead of print)","journal-title":"JAMA Oncol"},{"key":"3237_CR23","doi-asserted-by":"crossref","unstructured":"Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L et al (2016) Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006 [Abstract]. J Clin Oncol 34(suppl; abstr 9504)","DOI":"10.1200\/JCO.2016.34.15_suppl.9504"},{"key":"3237_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30259","author":"AN Shoushtari","year":"2016","unstructured":"Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK et al (2016) The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. doi: 10.1002\/cncr.30259 (Epub ahead of print)","journal-title":"Cancer"},{"key":"3237_CR25","doi-asserted-by":"publisher","unstructured":"Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM et al (2016) Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. doi: 10.1002\/cncr.30258 (Epub ahead of print)","DOI":"10.1002\/cncr.30258"},{"key":"3237_CR26","doi-asserted-by":"publisher","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23e34. doi: 10.1056\/NEJMoa1504030 .","DOI":"10.1056\/NEJMoa1504030"},{"key":"3237_CR27","doi-asserted-by":"crossref","unstructured":"Long GV, Atkinson V, Cebon J, Jameson M, Fitzharris B, McNeil C et al (2016) Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort [Abstract]. J Clin Oncol 34(suppl; abstr 9506)","DOI":"10.1200\/JCO.2016.34.15_suppl.9506"},{"key":"3237_CR28","doi-asserted-by":"crossref","unstructured":"Long GV, Dummer R, Ribas A, Puzanov I, VanderWalde A, Hans R et al (2016) Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma [Abstract]. J Clin Oncol 34(suppl; abstr 9568)","DOI":"10.1200\/JCO.2016.34.15_suppl.9568"},{"issue":"Suppl 2","key":"3237_CR29","doi-asserted-by":"publisher","first-page":"O7","DOI":"10.1186\/2051-1426-3-S2-O7","volume":"3","author":"TC Gangadhar","year":"2015","unstructured":"Gangadhar TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Luke JJ et al (2015) Preliminary results from a Phase I\/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers. J Immuno Ther Cancer 3(Suppl 2):O7. doi: 10.1186\/2051-1426-3-S2-O7","journal-title":"J Immuno Ther Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3237-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3237-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3237-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T13:47:29Z","timestamp":1589723249000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3237-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,11]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["3237"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3237-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,11]]}}}